A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL

NCT05883085 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Pheochromocytoma
Paraganglioma

Interventions

DRUG: Anlotinib hydrochloride

Sponsor

Peking Union Medical College Hospital